Liberty Biosecurity has developed a proprietary biological drug compound that degrades polymicrobial biofilms produced by pathogens in human wounds. LX-113, formerly designated as Advanced Decontamination and Bio-Neutralization Material (ADBM), this compound is being developed into a portfolio of compound derivatives targeted at multiple types of pathogenic biofilms.
LX-113 will be submitted to the U.S. Food and Drug Administration as an Investigative New Drug, with the indication of use as a topical therapy to enhance wound healing in neuropathic diabetic foot ulcers. Globally, this condition afflicts up to 35% of the 422 million people living with diabetes, while in the US alone, diabetic limb complications result in an annual direct cost of $17 billion/year.
The LX-113 powder has a variety of functional attributes that can be used for commercial, industrial, and medical applications.
LX-133 Against Indian Diabetic Foot Infections
Globally, 422 million people have diabetes, and the number of people diagnosed with this illness is increasing by 10.6% annually. 80% of people with diabetes live in low- to middle-income countries including India, a country with the second largest number of diabetic patients after China. India has 124.5 million diabetics of whom up to 25% will be stricken with a diabetic foot ulcer during their lifetimes.
“ As compared to the West, which have predominant Gram-positive infections, centers throughout India have reported a consistent Gram-negative bacterial preponderance in diabetic foot infections.” 
LX-113 was resuspended at a 1% weight to volume in saline and applied to all aerobic isolates in the seven studies conducted across India. The treatment lasted for four hours and was conducted at 55 degrees Celsius. LX-113’s effectiveness in defeating these Indian-specific biofilms: LX-113 destroyed 37% of the complex multispecies biofilm assay designed to mimic the clinical challenges these species inflict on India’s diabetics.
LX-113 is also currently being grown in the presence of antibiotics, and with over forty-eight generations, LX-113 has shown no indication of antibiotic resistance.
Liberty’s clinical trial program for LX-113 is supervised by the following physicians and scientists: